1. Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression
- Author
-
Eric S. Geanes, Sean M. Holloran, Anuradha Roy, Olivia K. Provance, Sumedha Gunewardena, Christy R. Hagan, Scott Weir, Asona Lui, and Joan Lewis-Wambi
- Subjects
Adult ,0301 basic medicine ,Cancer Research ,Down-Regulation ,Alpha interferon ,Triple Negative Breast Neoplasms ,Biology ,Article ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Downregulation and upregulation ,Cell Movement ,In vivo ,Interferon ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Parthenolide ,Triple-negative breast cancer ,Aged ,Cell Proliferation ,Tissue microarray ,NF-kappa B ,Interferon-alpha ,Middle Aged ,Antigens, Differentiation ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Oncology ,chemistry ,Tumor progression ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Signal Transduction ,medicine.drug - Abstract
Overexpression of interferon induced transmembrane protein-1 (IFITM1) enhances tumor progression in multiple cancers, but its role in triple-negative breast cancer (TNBC) is unknown. Here, we explore the functional significance and regulation of IFITM1 in TNBC and strategies to target its expression. Immunohistochemistry staining of a tissue microarray demonstrates that IFITM1 is overexpressed in TNBC samples which is confirmed by TCGA analysis. Targeting IFITM1 by siRNA or CRISPR/Cas9 in TNBC cell lines significantly inhibits proliferation, colony formation, and wound healing in vitro. Orthotopic mammary fat pad and mammary intraductal studies reveal that loss of IFITM1 reduces TNBC tumor growth and invasion in vivo. RNA-seq analysis of IFITM1/KO cells reveals significant downregulation of several genes involved in proliferation, migration, and invasion and functional studies identified NF-κB as an important downstream target of IFITM1. Notably, siRNA knockdown of p65 reduces IFITM1 expression and a drug-repurposing screen of FDA approved compounds identified parthenolide, an NFκB inhibitor, as a cytotoxic agent for TNBC and an inhibitor of IFITM1 in vitro and in vivo. Overall, our findings suggest that targeting IFITM1 by suppressing interferon-alpha/NFκB signaling represents a novel therapeutic strategy for TNBC treatment.
- Published
- 2021
- Full Text
- View/download PDF